ArticleReviews in urology2008
Overactive bladder: pharmacologic treatments in the neurogenic population.
Article in Reviews in urology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Bladder training for treating overactive bladder in adults.The Cochrane database of systematic reviews · 2023Pooled it
- Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity.Pharmacology research & perspectives · 2020Trial
- Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database.Advances in therapy · 2023Observational
- Diagnosis and Treatment of Japanese Children with Neurogenic Bladder: Analysis of Data from a National Health Insurance Database.Journal of clinical medicine · 2023Article
- Long-Term Surveillance and Management of Urological Complications in Chronic Spinal Cord-Injured Patients.Journal of clinical medicine · 2022Review
- The Effectiveness in Activating M-Type KInternational journal of molecular sciences · 2021Article
- Receptors, channels, and signalling in the urothelial sensory system in the bladder.Nature reviews. Urology · 2016Review
- The evaluation and management of refractory neurogenic overactive bladder.Current urology reports · 2014Review
- Functional expression of SK channels in murine detrusor PDGFR+ cells.The Journal of physiology · 2013Article
- Management of lower urinary tract dysfunction in patients with neurological disorders.Korean journal of urology · 2012Article
- Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA.Journal of the West African College of SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with neurologic disease commonly develop overactive bladder (OAB) symptoms of urgency, frequency, and/or urge incontinence. Although treatment for idiopathic OAB has been extensively studied, therapy for those individuals with neurogenic-mediated OAB has not been thoroughly evaluated. Included in the present article is a description of micturition neurophysiology and a neurourologic evaluation scheme. The pharmacologic treatment options for neurogenic OAB, mainly antimuscarinics and chemical denervation, are reviewed and important studies are discussed. Management of OAB in the neurogenic population is a complex issue with no uniform treatment strategy, and individualized treatment with first-line pharmacologic therapy is often recommended.
Indexed as
Identifiers
18836537PMC2556485W332979860What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.